Literature DB >> 26564699

[Burden of colorectal cancer in China].

Yue Zhang1, Jufang Shi2, Huiyao Huang1, Jiansong Ren1, Ni Li1, Min Dai1.   

Abstract

OBJECTIVE: To understand the incidence and mortality of colorectal cancer in China.
METHODS: The data from GLOBOCAN 2012, Chinese Cancer Registry Annual Report 2012, Cancer Incidence in Five Continents (CI5), the Three National Death Cause Surveys in China and WHO Mortality Database were used to learn about the incidence and mortality of colorectal cancer and related trends in China.
RESULTS: It was estimated by GLOBOCAN 2012 that in 2012 the age-standardized incidence of colorectal cancer in China was 16.9 per 100 000 in males and 11.6 per 100 000 in females, and the age-standardized mortality was 9.0 per 100 000 in males and 6.1 per 100 000 in females. GLOBOCAN 2012 estimated that colorectal cancer incidence and mortality would increase with the level of human development index. China's human development level was high, suggesting that the burden of colorectal cancer would be more serious in China with the development of social economy. The data from CI5 Volume IV and GLOBOCAN 2012 indicated that the incidence of colorectal cancer began to increase obviously at age of 50 years in China. Chinese Cancer Registry Annual Report 2012 showed that the incidence and mortality of colorectal cancer in urban population were two times higher than those in rural population in 2009, the proportions of colon cancer among colorectal and anus cancers, which was 49.0% in males and 54.2% in females, 53.4% in urban population and 41.7% in rural population. CI5 Volumes IV-X showed that colon cancer and rectum and anus cancer incidence in Shanghai for both males and females were increasing during the period 1973-2007. The percentage change in colon cancer and rectum and anus cancer incidence between 1973-1977 and 2003-2007 increased by 138.8% and 31.1% in males, 146.7% and 49.1% in females, respectively. The data from the Three National Death Cause Surveys showed that the crude mortality of colorectal cancer increased by 77.9% form mid 1970's (1973-1975) to mid 2000's (2004-2005). WHO Mortality Database showed that average annual percentage change (AAPC) of age-standardized colorectal cancer mortality increased by 0.7% (P < 0.05) from 1987 to 2000.
CONCLUSION: More attention should be paid to the prevention and control of colorectal cancer in urban area and in male population in China. Similar to the western countries, the burden of colorectal cancer in China would continue to become serious if no population based prevention and control programs are conducted.

Entities:  

Mesh:

Year:  2015        PMID: 26564699

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  16 in total

1.  Association Between Use of Traditional Chinese Medicine Herbal Therapy and Survival Outcomes in Patients With Stage II and III Colorectal Cancer: A Multicenter Prospective Cohort Study.

Authors:  Yun Xu; Jun J Mao; Lingyun Sun; Lin Yang; Jie Li; Yingxu Hao; Huashan Li; Wei Hou; Yuping Chu; Yu Bai; Xiaoqiang Jia; Jinwan Wang; Lin Shen; Ying Zhang; Jianbin Wang; Jianping Liu; Yufei Yang
Journal:  J Natl Cancer Inst Monogr       Date:  2017-11-01

2.  Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth.

Authors:  Ke Zhang; Ye Wang; Xiaoli Yu; Yanyan Shi; Yasai Yao; Xiaofang Wei; Xuezhen Ma
Journal:  BMC Cancer       Date:  2017-12-28       Impact factor: 4.430

3.  LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition.

Authors:  Bin Wang; Lanzhi Zhang; Liying Zhao; Rui Zhou; Yanqing Ding; Guoxin Li; Liang Zhao
Journal:  Cell Commun Signal       Date:  2017-06-12       Impact factor: 5.712

4.  KRT18 is correlated with the malignant status and acts as an oncogene in colorectal cancer.

Authors:  Jingfeng Zhang; Sifeng Hu; Yansen Li
Journal:  Biosci Rep       Date:  2019-08-13       Impact factor: 3.840

5.  Overexpression of miR-671-5p indicates a poor prognosis in colon cancer and accelerates proliferation, migration, and invasion of colon cancer cells.

Authors:  Wei Jin; Jinsheng Shi; Meiqin Liu
Journal:  Onco Targets Ther       Date:  2019-08-22       Impact factor: 4.147

6.  Cancer burden of major cancers in China: A need for sustainable actions.

Authors:  Maomao Cao; He Li; Dianqin Sun; Wanqing Chen
Journal:  Cancer Commun (Lond)       Date:  2020-05-02

7.  Elevated transgelin/TNS1 expression is a potential biomarker in human colorectal cancer.

Authors:  Huimin Zhou; Yiming Zhang; Lihao Wu; Wenrui Xie; Lan Li; Yu Yuan; Yu Chen; Ying Lin; Xinxiang He
Journal:  Oncotarget       Date:  2017-12-15

8.  Alpha B-crystallin C-802G polymorphism and colorectal cancer susceptibility and clinical outcome in Chinese population.

Authors:  Xiao Wu; Yuan-Zheng Zheng; Bin Han; Ke Wang
Journal:  Sci Rep       Date:  2018-08-06       Impact factor: 4.379

9.  RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources.

Authors:  Bin Wu; Yuan Yao; Ke Zhang; Xuezhen Ma
Journal:  Oncotarget       Date:  2017-04-11

10.  LncRNA LINC00662 promotes colon cancer tumor growth and metastasis by competitively binding with miR-340-5p to regulate CLDN8/IL22 co-expression and activating ERK signaling pathway.

Authors:  Bo Cheng; Aimei Rong; Quanbo Zhou; Wenlu Li
Journal:  J Exp Clin Cancer Res       Date:  2020-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.